Chu X - Search Results

1

A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy.

Li S, Chu X, Ye L, Ni J, Zhu Z. Li S, et al. Among authors: chu x. Transl Lung Cancer Res. 2020 Oct;9(5):2082-2096. doi: 10.21037/tlcr-20-512. Transl Lung Cancer Res. 2020. PMID: 33209628 Free PMC article. Review.

2

Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Guo T, Chu L, Chu X, Yang X, Li Y, Zhou Y, Xu D, Zhang J, Wang S, Hu J, Chu Q, Moran T, Cho WC, Merrell KW, Rizzo S, Liu Y, Ni J, Zhu Z. Guo T, et al. Among authors: chu q, chu l, chu x. Transl Lung Cancer Res. 2022 Feb;11(2):173-187. doi: 10.21037/tlcr-22-54. Transl Lung Cancer Res. 2022. PMID: 35280308 Free PMC article.

3

Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.

Ni J, Guo T, Li Y, Yang X, Li Y, Zou L, Chu L, Chu X, Li S, Ye L, Zhang Y, Zhu Z. Ni J, et al. Among authors: chu l, chu x. Transl Lung Cancer Res. 2019 Dec;8(6):967-978. doi: 10.21037/tlcr.2019.12.02. Transl Lung Cancer Res. 2019. PMID: 32010575 Free PMC article.

4

Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.

Zhou Y, Wang B, Qu J, Yu F, Zhao Y, Li S, Zeng Y, Yang X, Chu L, Chu X, Li Y, Zou L, Guo T, Ye L, Liang F, Wang S, Liu Q, Ni J, Zhu Z. Zhou Y, et al. Among authors: chu l, chu x. Lung Cancer. 2020 Dec;150:178-185. doi: 10.1016/j.lungcan.2020.10.018. Epub 2020 Nov 5. Lung Cancer. 2020. PMID: 33186860

5

Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy.

Guo T, Zou L, Ni J, Chu X, Zhu Z. Guo T, et al. Among authors: chu x. Transl Lung Cancer Res. 2020 Oct;9(5):2097-2112. doi: 10.21037/tlcr-20-511. Transl Lung Cancer Res. 2020. PMID: 33209629 Free PMC article. Review.

6

A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.

Zhou Y, Yu F, Zhao Y, Zeng Y, Yang X, Chu L, Chu X, Li Y, Zou L, Guo T, Zhu Z, Ni J. Zhou Y, et al. Among authors: chu l, chu x. Transl Lung Cancer Res. 2020 Dec;9(6):2479-2493. doi: 10.21037/tlcr-20-1145. Transl Lung Cancer Res. 2020. PMID: 33489808 Free PMC article. Review.

7

Identification and Integrated Analysis of circRNA and miRNA of Radiation-Induced Lung Injury in a Mouse Model.

Li Y, Zou L, Chu L, Ye L, Ni J, Chu X, Guo T, Yang X, Zhu Z. Li Y, et al. Among authors: chu l, chu x. J Inflamm Res. 2021 Sep 2;14:4421-4431. doi: 10.2147/JIR.S322736. eCollection 2021. J Inflamm Res. 2021. PMID: 34511976 Free PMC article.

8

A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer.

Ni J, Zhou Y, Wang S, Guo T, Hu J, Chu Q, Yang X, Chu L, Chu X, Li Y, Zhu Z. Ni J, et al. Among authors: chu q, chu l, chu x. Cancer Immunol Immunother. 2022 May;71(5):1275-1280. doi: 10.1007/s00262-021-03070-8. Epub 2021 Oct 6. Cancer Immunol Immunother. 2022. PMID: 34613418 Free PMC article.

9

Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.

Zhao Y, Li S, Yang X, Chu L, Wang S, Tong T, Chu X, Yu F, Zeng Y, Guo T, Zhou Y, Zou L, Li Y, Ni J, Zhu Z. Zhao Y, et al. Among authors: chu l, chu x. Int J Cancer. 2022 Apr 15;150(8):1318-1328. doi: 10.1002/ijc.33904. Epub 2022 Jan 6. Int J Cancer. 2022. PMID: 34914096

10

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.

Zeng Y, Guo T, Zhou Y, Zhao Y, Chu L, Chu X, Yang X, Ni J, Zhu Z. Zeng Y, et al. Among authors: chu l, chu x. BMC Cancer. 2022 Feb 21;22(1):198. doi: 10.1186/s12885-022-09245-5. BMC Cancer. 2022. PMID: 35189835 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,459 results

Search Page